239 related articles for article (PubMed ID: 19276372)
1. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Ma O; Cai WW; Zender L; Dayaram T; Shen J; Herron AJ; Lowe SW; Man TK; Lau CC; Donehower LA
Cancer Res; 2009 Mar; 69(6):2559-67. PubMed ID: 19276372
[TBL] [Abstract][Full Text] [Related]
2. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Cheng L; Zhou Z; Flesken-Nikitin A; Toshkov IA; Wang W; Camps J; Ried T; Nikitin AY
Oncogene; 2010 Oct; 29(42):5700-11. PubMed ID: 20676140
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.
Grabinger T; Bode KJ; Demgenski J; Seitz C; Delgado ME; Kostadinova F; Reinhold C; Etemadi N; Wilhelm S; Schweinlin M; Hänggi K; Knop J; Hauck C; Walles H; Silke J; Wajant H; Nachbur U; W Wei-Lynn W; Brunner T
Gastroenterology; 2017 Mar; 152(4):867-879. PubMed ID: 27889570
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of the
Lee MK; Noh JK; Woo SR; Kong M; Lee YC; Lee JW; Ko SG; Eun YG
Cancer Genomics Proteomics; 2022; 19(5):591-605. PubMed ID: 35985688
[TBL] [Abstract][Full Text] [Related]
5. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of BIRC2 and BIRC3 expression by inflammatory cytokines and glucocorticoids in pulmonary epithelial cells.
Thorne A; Bansal A; Necker-Brown A; Mostafa MM; Gao A; Georgescu A; Kooi C; Leigh R; Newton R
PLoS One; 2023; 18(6):e0286783. PubMed ID: 37289679
[TBL] [Abstract][Full Text] [Related]
7. BIRC2 amplification in squamous cell carcinomas of the uterine cervix.
Choschzick M; Tabibzada AM; Gieseking F; Woelber L; Jaenicke F; Sauter G; Simon R
Virchows Arch; 2012 Aug; 461(2):123-8. PubMed ID: 22733500
[TBL] [Abstract][Full Text] [Related]
8. BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia.
Roohollahi K; de Jong Y; Pai G; Zaini MA; de Lint K; Sie D; Rooimans MA; Rockx D; Hoskins EE; Ameziane N; Wolthuis R; Joenje H; Wells SI; Dorsman J
Sci Rep; 2022 Jan; 12(1):45. PubMed ID: 34997070
[TBL] [Abstract][Full Text] [Related]
9. Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma.
Rao PH; Zhao S; Zhao YJ; Yu A; Rainusso N; Trucco M; Allen-Rhoades W; Satterfield L; Fuja D; Borra VJ; Man TK; Donehower LA; Yustein JT
Genes Chromosomes Cancer; 2015 Dec; 54(12):796-808. PubMed ID: 26355645
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
Lu XY; Lu Y; Zhao YJ; Jaeweon K; Kang J; Xiao-Nan L; Ge G; Meyer R; Perlaky L; Hicks J; Chintagumpala M; Cai WW; Ladanyi M; Gorlick R; Lau CC; Pati D; Sheldon M; Rao PH
Mol Cancer Res; 2008 Jun; 6(6):937-46. PubMed ID: 18567798
[TBL] [Abstract][Full Text] [Related]
11. Gene network revealed involvements of Birc2, Birc3 and Tnfrsf1a in anti-apoptosis of injured peripheral nerves.
Wang Y; Tang X; Yu B; Gu Y; Yuan Y; Yao D; Ding F; Gu X
PLoS One; 2012; 7(9):e43436. PubMed ID: 23028454
[TBL] [Abstract][Full Text] [Related]
12. BIRC3 single nucleotide polymorphism associate with asthma susceptibility and the abundance of eosinophils and neutrophils.
Roscioli E; Hamon R; Ruffin RE; Grant J; Hodge S; Zalewski P; Lester S
J Asthma; 2017 Mar; 54(2):116-124. PubMed ID: 27304223
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential.
Yamato A; Soda M; Ueno T; Kojima S; Sonehara K; Kawazu M; Sai E; Yamashita Y; Nagase T; Mano H
Cancer Sci; 2015 Sep; 106(9):1137-42. PubMed ID: 26094954
[TBL] [Abstract][Full Text] [Related]
14. Increased Expression of
Gil-Kulik P; Świstowska M; Kondracka A; Chomik P; Krzyżanowski A; Kwaśniewska A; Rahnama M; Kocki J
Oxid Med Cell Longev; 2020; 2020():9084730. PubMed ID: 32322338
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
16. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Kresse SH; Ohnstad HO; Paulsen EB; Bjerkehagen B; Szuhai K; Serra M; Schaefer KL; Myklebost O; Meza-Zepeda LA
Genes Chromosomes Cancer; 2009 Aug; 48(8):679-93. PubMed ID: 19441093
[TBL] [Abstract][Full Text] [Related]
17. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.
Pourebrahim R; Zhang Y; Liu B; Gao R; Xiong S; Lin PP; McArthur MJ; Ostrowski MC; Lozano G
Genes Dev; 2017 Sep; 31(18):1847-1857. PubMed ID: 29021240
[No Abstract] [Full Text] [Related]
18. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.
Zender L; Spector MS; Xue W; Flemming P; Cordon-Cardo C; Silke J; Fan ST; Luk JM; Wigler M; Hannon GJ; Mu D; Lucito R; Powers S; Lowe SW
Cell; 2006 Jun; 125(7):1253-67. PubMed ID: 16814713
[TBL] [Abstract][Full Text] [Related]
20. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome.
Labbé K; McIntire CR; Doiron K; Leblanc PM; Saleh M
Immunity; 2011 Dec; 35(6):897-907. PubMed ID: 22195745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
